BGB-43395

N/A

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug NameBGB-43395
Drug Alias NameBGB-43395BGB43395
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 4
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesThailandNew Zealand +[11] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeOne Medicines Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBeOne Medicines LtdBeigene (Suzhou) Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A